Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20079665 | 0.75 | HDAC1 (0.48) | SMN1; SMN2YTHDC1 | |
| SCHEMBL10114423 | 0.75 | RXFP1 (0.65) | TP53KMT2AMEN1POLB | |
| SCHEMBL10114442 | 0.74 | RXFP1 (0.64) | TP53KMT2AMEN1POLB | |
| SCHEMBL20079735 | 0.71 | POLB (0.48) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL20079742 | 0.69 | SMN1; SMN2 (0.52) | RAB9ANPC1SMN1; SMN2RECQLKMT2A | |
| SCHEMBL20079645 | 0.68 | CYP11B2 (0.44) | TP53KMT2AMEN1MAPTYTHDC1 | |
| SCHEMBL20079660 | 0.67 | ALDH1A1 (0.51) | SMN1; SMN2KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL10280149 | 0.66 | TRPA1 (0.36) | YTHDC1 | |
| SCHEMBL20079775 | 0.66 | PTGS2 (0.43) | TP53KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL21133621 | 0.66 | ALDH1A1 (0.48) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | RAB9A 2306/4885NPC1 73/4885SMN1; SMN2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.